Astellas Will Give Cardiome Accelerated Milestone Payment For Atrial Fibrillation Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised agreement is a show of “confidence” following FDA’s refusal to file the original application for RSD1235.
You may also be interested in...
Astellas Pharma’s Vernakalant For Atrial Fibrillation Goes Before FDA Panel
FDA’s Cardiovascular and Renal Drugs Advisory Committee considers Astellas’ NDA re-submission for the indication Dec. 11.
Astellas Pharma’s Vernakalant For Atrial Fibrillation Goes Before FDA Panel
FDA’s Cardiovascular and Renal Drugs Advisory Committee considers Astellas’ NDA re-submission for the indication Dec. 11.
Cardiome/Astellas’ Vernakalant IV ACT 2 Study Positive For Post-Surgical Atrial Fibrillation
Study could bode well for oral formulation for maintenance of heart rhythm after atrial fibrillation.